AstraZeneca settles Crestor lawsuit
The Local Sweden - [email protected]
Published: 25 Mar, 2013 CET.
Updated: Mon 25 Mar 2013 14:58 CET
Anglo-Swedish pharmaceutical company AstraZeneca on Monday said it had settled a long-running patent lawsuit over its top-selling drug Crestor.
AstraZeneca said in a statement that the deal would protect its sales of the anti-cholesterol drug until 2016.
"AstraZeneca today announced that it has entered into a settlement agreement in its US patent infringement litigation against Watson Laboratories, Inc., Actavis, Inc. (formerly known as Watson Pharmaceuticals, Inc.), and EGIS Pharmaceuticals," the company said.
Crestor generated $6.25 billion of sales in 2012, down from $6.6 billion in 2011 after losing patent protection in certain regions.
AstraZeneca's announcement comes after it last week said it was cutting 3,900 jobs - in a major restructuring of the group over the next three years.
The group currently employs about 57,000 staff worldwide.
AFP/The Local/og
Comments
See Also
AstraZeneca said in a statement that the deal would protect its sales of the anti-cholesterol drug until 2016.
"AstraZeneca today announced that it has entered into a settlement agreement in its US patent infringement litigation against Watson Laboratories, Inc., Actavis, Inc. (formerly known as Watson Pharmaceuticals, Inc.), and EGIS Pharmaceuticals," the company said.
Crestor generated $6.25 billion of sales in 2012, down from $6.6 billion in 2011 after losing patent protection in certain regions.
AstraZeneca's announcement comes after it last week said it was cutting 3,900 jobs - in a major restructuring of the group over the next three years.
The group currently employs about 57,000 staff worldwide.
AFP/The Local/og
Join the conversation in our comments section below. Share your own views and experience and if you have a question or suggestion for our journalists then email us at [email protected].
Please keep comments civil, constructive and on topic – and make sure to read our terms of use before getting involved.
Please log in here to leave a comment.